What is the revenue and EPS growth rate for West Pharmaceutical year over year?

What guidance did West Pharmaceutical's management provide for the next earnings period?

What is the market's earnings forecast for West Pharmaceutical next quarter?

Did West Pharmaceutical beat or miss consensus estimates last quarter?

What is West Pharmaceutical's gross profit margin?

What factors drove the changes in West Pharmaceutical's revenue and profit?

What were the key takeaways from West Pharmaceutical's earnings call?

What were the key takeaways from West Pharmaceutical’s earnings call?

- **Q4 Revenue Beat**: $805M (+7.5% reported, 3.3% organic), driven by 15.1% HVP components growth.
- **EPS & Cash Flow Strength**: Adjusted EPS $2.04 (+12%), free cash flow $469M (70% YoY growth).
- **GLP-1 Outlook**: 10% 2026 growth midpoint, conservative vs. 50%+ 2025 expansion.
- **Strategic Moves**: SmartDose sale midyear, $250M-$275M 2026 CapEx for HVP capacity.
- **Annex 1 Growth**: 200+ bps 2026 contribution from 6B component upgrades.

**【CEO Summary Section】**
West Pharmaceutical Services reported Q4 2025 revenue of $805 million, exceeding expectations with 7.5% reported growth and 3.3% organic growth. Adjusted EPS of $2.04 rose 12% year-over-year, driven by high-value product (HVP) components, particularly GLP-1 elastomers. Free cash flow reached $175 million, more than double the prior year. Key highlights include:
- **HVP Components Growth**: $390 million in Q4, up 15.1% organically, led by GLP-1s and Annex 1 upgrades.
- **Synchrony Launch**: New prefillable syringe system launched commercially, offering end-to-end regulatory support.
- **SmartDose Sale**: Expected midyear closure, aligning with strategic focus on HVP growth.
- **CM Segment Expansion**: Dublin drug handling operations commenced, targeting mid- to high-teens profitability.

**【CFO Financial Commentary】**
- **Q4 Financials**: GAAP net income $420 million; Non-GAAP EPS $1.08, beating estimates. Gross margin improved 130 bps to 37.8% due to HVP mix.
- **2026 Guidance**: 5-7% organic revenue growth ($3.215B-$3.275B) and EPS $7.85-$8.20. HVP components expected to drive 5+ points of growth, with GLP-1s at 10% midpoint (conservative outlook).
- **Cash Flow & Capital Allocation**: Full-year free cash flow $469 million (70% YoY growth). 2026 CapEx $250M-$275M, prioritizing HVP capacity. Share buybacks and M&A under consideration.

**【Q&A Key Highlights】**
- **GLP-1 Growth & Orals Impact**: Management reaffirmed injectable GLP-1 resilience, citing low oral penetration (8/10 new users) and pipeline expansion. 2026 GLP-1 growth at 10% midpoint reflects cautious assumptions.
- **Annex 1 Momentum**: 700 projects initiated (half completed), with 65 Q4 closes. 2026 target: 200+ basis points of growth from HVP upgrades.
- **Capacity Constraints**: HVP components outside GLP-1s outstripped supply; 2026 investments in European and U.S. plants to address demand.
- **Free Cash Flow Utilization**: Proceeds from SmartDose ($120M-$130M) and strong cash balance ($791M) may support M&A or buybacks.


West Pharmaceutical Services, Inc. (WST) Q4 2025 Earnings Call Transcript

- **Q3 Beat and Guidance Update**: Revenue $805M (+5% organic), EPS $1.96. FY2025 revenue raised to $3.06-$3.07B, EPS $7.06-$7.11.
- **HVP Components Surge**: +13% organic growth, driven by GLP-1s (9% of sales), biologics, and 375 Annex 1 projects.
- **2026 Outlook**: HVP Components to lead double-digit growth, offsetting $40M CGM exit with new high-margin business.
- **Margin Expansion**: Gross margin +120bps YoY, free cash flow +54% YoY. 2026 automation and network optimization to drive further margin gains.

**【CEO Summary Section】**
- **Q3 2025 Performance**: Revenue of $805 million (+5% organic), adjusted EPS of $1.96 (+6% YoY), and operating margin of 21.1%. Guidance updated to $3.06-$3.07 billion in revenue and $7.06-$7.11 in EPS for FY2025.
- **HVP Components Growth**: $390 million (+13% organic), driven by GLP-1s (9% of total sales), biologics, and Annex 1 upgrades (375 ongoing projects). Annex 1 expected to contribute 200bps of growth in 2025.
- **Contract Manufacturing**: $157 million (+4.9% organic), with Dublin facility ramping for drug handling ($20M+ in 2026).
- **Leadership Updates**: New CFO Bob McMahon and CTO Devesh Mathur appointed to accelerate growth and innovation.

**【CFO Financial Commentary】**
- **Financial Highlights**: Gross margin 36.6% (+120bps YoY), free cash flow $294 million (+54% YoY), and capital expenditures $210 million (FY2025 guidance: $275 million).
- **Guidance Update**: FY2025 revenue $3.06-$3.07 billion (+5.8%-6.1% reported), Q4 revenue $790-$800 million (+1%-2.3% organic). FY2025 EPS $7.06-$7.11 (+4.6%-5.3%).
- **2026 Outlook**: HVP Components to lead growth, with CGM contract exit ($40M headwind) offset by new high-margin business in Dublin.

**【Q&A Key Highlights】**
- **Long-Term Growth Drivers**: HVP Components (GLP-1s, Annex 1) expected to sustain double-digit growth. GLP-1s grew >50% in 2025, driven by pipeline expansion and generics.
- **Margin Expansion**: Gross margin to improve via HVP mix, automation (SmartDose 3.6 in 2026), and network optimization. 2026 free cash flow expected to expand with lower CapEx.
- **Annex 1 Momentum**: 375 projects in pipeline, with 40%+ conversion rate to commercial production. Dublin facility to add $20M+ in 2026.
- **Tariff Mitigation**: >50% of 2025 tariff costs mitigated, full mitigation expected in 2026.

West Pharmaceutical Services, Inc. (WST) Q3 2025 Earnings Call Transcript

- **Revenue Beat**: Q2 net sales $766.5M (+9.2% YoY), driven by 8.4% organic growth in Proprietary Products.
- **Margin Expansion**: Gross margin 35.7% (up 290bps YoY), fueled by HVP components at 40.1% margin.
- **Guidance Uptick**: FY25 sales raised to $3.04-3.06B (vs. $2.945-2.975B), EPS to $6.65-6.85 (vs. $6.15-6.35).
- **Strategic Growth**: 370 Annex-1 projects, GLP-1 at 8% revenue, and $146.5M YTD CapEx for capacity expansion.
- **Risk Mitigation**: Tariffs expected to cost $15-20M FY25, with automation investments (e.g., SmartDose line in 2026) to offset costs.

**【CEO Opening Remarks】**
- Q2 2025 net sales grew 9.2% year-over-year, with 6.8% organic growth, driven by HVP components and GLP-1 elastomer demand.
- Proprietary Products segment grew 8.4% organically, led by 11.3% HVP component expansion and 8% GLP-1 elastomer revenue contribution.
- 370 Annex-1 HVP upgrade projects (up from 340 last quarter), positioning for multiyear growth in biologics and generics.
- Updated FY25 guidance: $3.04-3.06B net sales (vs. prior $2.945-2.975B) and $6.65-6.85 EPS (vs. $6.15-6.35).

**【CFO Financial Review】**
- Q2 2025: $766.5M net sales, 35.7% gross margin (up 290bps YoY), 20.3% adjusted operating margin, and $1.08 EPS (21.1% YoY growth).
- HVP components gross margin improved 310bps to 40.1%, driven by price hikes and higher-margin product mix.
- FY25 CapEx maintained at $275M, with $146.5M spent YTD (down $44.3M YoY due to deferred projects).
- Tariffs expected to impact FY25 by $15-20M (vs. prior $20-25M estimate), with mitigation efforts underway.

**【Q&A Highlights】**
- **GLP-1 Growth**: 8% of Q2 revenue, up from 7% last quarter, driven by multi-drug demand and pandemic-era capacity utilization.
- **Annex-1 Timeline**: 150bps contribution in FY25, with projects taking 12-18 months to commercialize.
- **Tariff Assumptions**: Guidance reflects current rates, with potential upside if proposed tariffs are not implemented.
- **SmartDose Automation**: New line in early 2026 expected to improve economics, though margin specifics not disclosed.
- **Generic Drug Destocking**: Q2 normalization in pharma, but generics still facing destocking headwinds.


West Pharmaceutical Services, Inc. (WST) Q2 2025 Earnings Call Transcript

- **Q1 Revenue Beat**: $698M with 2.1% organic growth, driven by GLP-1 demand and reduced destocking.
- **HVP Components Growth**: Mid-single digits expected in 2025, supported by 7% GLP-1 laser revenue in Q1.
- **Biologics Recovery**: H2 high single-digit growth after Q1 destocking challenges.
- **Annex 1 Momentum**: 340 projects (up 21%) with Q1 revenue exceeding expectations at 200bps of total.
- **Tariff Mitigation**: $20-$25M annual headwind offset by FX and automation; exploring customer cost sharing.
- **SmartDose Automation**: Late 2025 launch to improve margins, with strategic exit options.
- **Drug Handling Expansion**: Dublin site targeting higher-margin contracts with early-stage customer traction.


**【CEO Summary Section】**
- West delivered Q1 2025 revenue of $698 million, with organic sales growth of 2.1%, driven by GLP-1 demand and reduced destocking impact.
- Proprietary Products segment grew 2.4% organically, with HVP components expected to grow mid-single digits in 2025, supported by GLP-1 laser business (7% of total revenue in Q1).
- Biologics HVP components faced Q1 challenges due to destocking but are expected to rebound with high single-digit growth in H2.
- Annex 1 projects reached 340, up from 280, with Q1 revenue contribution exceeding expectations at 200 basis points of total revenue.
- Dublin contract manufacturing site is ramping up, targeting drug handling for higher margins.
- SmartDose device margin improvement efforts include automation by late 2025, with all strategic options still on the table.

**【CFO Financial Commentary】**
- Q1 GAAP net income was $420 million, with adjusted EPS of $1.08 (excluding stock-based compensation tax benefits), up 1.4% YoY.
- Gross profit margin improved to 33.2% (30 bps YoY), driven by Proprietary Products margin expansion to 37.3%.
- Operating cash flow of $129.4 million, up 9.5% YoY, supported by working capital management.
- Full-year 2025 guidance updated to $2.945-$2.975 billion in revenue (2-3% organic growth) and $6.15-$6.35 in adjusted EPS, reflecting tariff mitigation efforts and cost control.
- Tariff-related headwind estimated at $20-$25 million for 2025, partially offset by FX improvements and Q1 tax benefits.

**【Q&A Key Takeaways】**
- **Utilization & Margins**: Dublin site utilization is low but expected to rise post-automation; margin improvements in E&PC and CM offset mix headwinds.
- **Tariff Mitigation**: Exploring customer cost pass-through and regional production to offset $20-$25M annual impact.
- **SmartDose Strategy**: Automation by late 2025 aims to improve margins; all exit options remain under evaluation.
- **Annex 1 Upside**: 340 projects in pipeline, with potential for mix shift to higher-margin services.
- **GLP-1 Growth**: Oral delivery competition seen as limited, with injectables retaining majority market share.
- **Drug Handling**: Dublin facility expansion targets higher-margin, lower-capital contracts, with early-stage customer engagement.


West Pharmaceutical Services (WST)-24 Apr 25-2025 Q1 Earnings call transcript

- **HVP Component Growth**: 2025 expected to deliver mid- to high single-digit growth, driven by Biologics, GLP-1s, and Annex 1 adoption.
- **CGM Exit Strategy**: Phasing out low-margin CGM business to focus on higher-margin GLP-1 devices, with 2025 CM margin decline of 200bps.
- **2025 Financial Targets**: Organic growth 2%-3%, adjusted EPS $6.00-$6.20, with $75M FX headwind and $0.43 EPS impact from device incentives.
- **Annex 1 Pipeline**: 200+ projects, 150+ expected to convert to HVP in 2025, contributing 100-150bps growth.
- **SmartDose Focus**: Doubling capacity in 2025, exploring automation and new customers to improve margins.

**【CEO Summary Section】**
- **2024 Strategic Achievements**: Growth in GLP-1 market, reduced manufacturing lead times, $560M shareholder returns, and HVP capacity expansion.
- **Q4 2024 Financial Highlights**: 3.3% organic revenue growth, Proprietary Products down 4.5% (improving trend), and 21.7% adjusted operating margin.
- **HVP Component Growth**: Expected mid- to high single-digit 2025 growth driven by Biologics, GLP-1s, and Annex 1 adoption.
- **SmartDose Device**: Capacity to double in 2025, but may dilute margins; exploring efficiency improvements.
- **Annex 1 Impact**: 200+ projects in pipeline, with 150+ expected to convert to HVP in 2025, contributing 100-150bps growth.

**【CFO Financial Commentary】**
- **Q4 2024 Results**: $748.8M net sales, 36.5% gross margin (down 150bps YoY), and $162.8M adjusted operating profit.
- **2025 Guidance**: Net sales $2.875B-$2.905B (2%-3% organic growth), adjusted EPS $6.00-$6.20.
- **Key Drivers**: HVP component margin expansion, GLP-1 CM growth offsetting CGM exit, and $275M CapEx decline.
- **Challenges**: $75M FX headwind, $0.43 EPS impact from device incentives and CGM exit, and $0.22 R&D/SG&A investments.

**【Q&A Key Takeaways】**
- **CGM Transition**: Exiting low-margin CGM business to focus on GLP-1 devices, with 2025 CM margin decline of 200bps.
- **GLP-1 Contribution**: 10% of total revenue (5% Proprietary, 40% CM), with CM GLP-1 share expected to grow.
- **SmartDose Strategy**: Evaluating all options to improve margins, including automation and new customer wins.
- **Annex 1 Pipeline**: 200+ projects, with 150+ expected to convert to HVP in 2025, supporting long-term growth.
- **2025 Outlook**: Return to organic growth driven by HVP components, with CM as a bridge to higher-margin activities.

Actual											1.01	1.25	1.15	1.34	2.05	2.46	2.06	2.04	2.3	2.47	2.03	1.77	1.98	2.11	2.16	1.83	1.56	1.52	1.85	1.82	1.45	1.84	1.96	2.04
Forecast											0.822	0.9075	0.994	1.125	1.4311	1.7398	1.7967	1.9155	2.1233	2.2075	2.12	1.3757	1.6683	1.9264	1.8567	1.7782	1.2734	1.7412	1.5007	1.7191	1.2275	1.5092	1.6848	1.8276
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+22.87%	+37.74%	+15.69%	+19.11%	+43.25%	+41.40%	+14.65%	+6.50%	+8.32%	+11.89%	-4.25%	+28.66%	+18.68%	+9.53%	+16.34%	+2.91%	+22.51%	-12.70%	+23.28%	+5.87%	+18.13%	+21.92%	+16.33%	+11.62%

WST

WST fundamentals

WST Q4 2025 Earnings

Earnings Call

You can ask Aime

WST

WST fundamentals

WST Q4 2025 Earnings

Earnings Call

WST Earnings Call Summary for Q4/20258:00 AM on Feb 12, 2026

WST Earnings Call Summary for Q3/20258:00 AM on Oct 23, 2025

WST Earnings Call Summary for Q2/20258:00 AM on Jul 24, 2025

WST Earnings Call Summary for Q1/20259:00 AM on Apr 24, 2025

WST Earnings Call Summary for Q4/20249:00 AM on Feb 13, 2025

You can ask Aime